Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review
Open Access
- 5 August 2020
- Vol. 12 (8), 2195
- https://doi.org/10.3390/cancers12082195
Abstract
Background: Menopausal hormone therapy (MHT) is an appropriate treatment for women with the climacteric syndrome. The estrogen component of MHT effectively alleviates climacteric symptoms but also stimulates the endometrium and thus may increase the risk of endometrial cancer (EC). Materials and Methods: We performed a systematic literature search of the databases PubMed and Cochrane Central Register of Controlled Trials to identify controlled and uncontrolled clinical trials reporting on the prevalence and/or incidence of EC among women using MHT. Results: 31 publications reporting on 21,306 women with EC diagnosed during or after MHT were identified. A significantly reduced risk of EC among continuous-combined (cc)MHT users with synthetic progestins (SPs) was demonstrated in 10/19 studies with odds ratios (ORs)/hazard ratios (HRs) between 0.24 and 0.71. Only one study documented an increased risk of EC among long-term users (≥10 years), not confirmed in three other sub-group analyses of women with ≥6, ≥5, and >10 years of ccMHT use. A significantly increased risk of EC among users of sequential-combined (sc)MHT with SPs was demonstrated in 6/12 studies with ORs/HRs between 1.38 and 4.35. Number of days of progestin per month was a significant modulator of EC risk. A decreased risk of EC was seen in obese women. Two studies documented an increased risk of EC among users of cc/scMHT with micronized progesterone. A significantly increased risk of EC among estrogen-only MHT users was demonstrated in 9/12 studies with ORs/HRs between 1.45 and 4.46. The adverse effect of estrogen-only MHT was greatest among obese women. Conclusion: ccMHT with SPs reduces the risk of EC, whereas estrogen-only MHT increases the risk. scMHT with SPs and cc/scMHT with micronized progesterone increase the risk of EC depending on type of progestin, progestin dosage, and duration of MHT use.This publication has 35 references indexed in Scilit:
- Menopausal hormone therapy and risk of endometrial cancerThe Journal of Steroid Biochemistry and Molecular Biology, 2014
- Recent changes in endometrial cancer trends among menopausal-age US womenCancer Epidemiology, 2013
- Long-term use of continuous-combined estrogen-progestin hormone therapy and risk of endometrial cancerCancer Causes & Control, 2011
- Variations in sex hormone metabolism genes, postmenopausal hormone therapy and risk of endometrial cancerInternational Journal of Cancer, 2011
- Ligand-Dependent Degradation of SRC-1 Is Pivotal for Progesterone Receptor Transcriptional ActivityMolecular Endocrinology, 2011
- Endometrial cancer associated with various forms of postmenopausal hormone therapy: A case control studyInternational Journal of Cancer, 2010
- Long-term Postmenopausal Hormone Therapy and Endometrial CancerCancer Epidemiology, Biomarkers & Prevention, 2010
- The influence of menopausal hormone therapy on tumour characteristics and survival in endometrial cancer patientsEuropean Journal of Cancer, 2009
- Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancerAmerican Journal of Obstetrics and Gynecology, 2004
- Hormone replacement therapy and incidence of hormone‐dependent cancers in the Norwegian Women and Cancer studyInternational Journal of Cancer, 2004